Home > Insider Trading > Filing (0000914475-25-000073)

Filing Details

Accession Number:: 0000914475-25-000073
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-14 18:57:31
Reporting Period:: 2025-02-13

Filing Date:: 2025-02-14
Accepted Time:: 2025-02-14 18:57:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1201096	Charles Kevin Gorman	12780 El Camino Real San Diego CA 92130		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-02-13	5,376	$0.00	524,450	No	4	M	Direct
Common Stock	Disposition	2025-02-13	2,832	$116.69	521,618	No	4	S	Direct
Common Stock	Acquisiton	2025-02-13	5,603	$0.00	527,221	No	4	M	Direct
Common Stock	Disposition	2025-02-13	3,012	$116.68	524,209	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2025-02-13	5,376	$0.00	5,376	$0.00
Common Stock	Restricted Stock Unit	Disposition	2025-02-13	5,603	$0.00	5,603	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,754			No	4	M	Direct
16,812			No	4	M	Direct

Footnotes

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.92 to $117.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $117.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, and will vest as to 5,377 shares on February 13, 2026, and 5,377 shares on February 13, 2027, subject to the terms and conditions of the award.
This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, and will vest as to 5,604 shares on February 13, 2026, 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award.